Methods of treating cancer with doxazolidine and prodrugs thereof
The invention provides therapeutically effective compounds for the prevention and treatment of cancer and pharmaceutical compositions containing these compounds as well as methods of using and administering these compounds. The invention also includes methods of activating a prodrug of these therapeutically effective compounds by the administration of a peptide-directed targeting construct that delivers a prodrug-activating enzyme to a target activation site.
1. An anthracycline-formaldehyde compound having the chemical formula:
or a pharmaceutically-acceptable salt thereof,
wherein R is a cycloalkyl group having between 3 and 20 carbon atoms, or an aryl group.
2. An anthracycline-formaldehyde compound having the chemical formula:
or a pharmaceutically-acceptable salt thereof,
wherein R is an alkyl group having between 1 and 100 carbon atoms.
3. An anthracycline-formaldehyde compound having the chemical formula:
or a pharmaceutically-acceptable salt thereof,
wherein R is a molecule removed by an enzyme present in a cancer cell.
4. An anthracycline-formaldehyde compound having the chemical formula:
or a pharmaceutically-acceptable salt thereof.
5. An anthracycline-formaldehyde compound having the chemical formula:
or a pharmaceutically-acceptable salt thereof.
6. An anthracycline-formaldehyde compound having the chemical formula:
or a pharmaceutically-acceptable salt thereof.
7. An anthracycline-formaldehyde compound having the chemical formula:
or a pharmaceutically-acceptable salt thereof.
8. An anthracycline-formaldehyde compound having the chemical formula:
or a pharmaceutically-acceptable salt thereof.
9. A pharmaceutical composition comprising
a. an anthracycline-formaldehyde compound selected from the group consisting of any of the compounds of claims 1 , 2 , 3 , 4 , 5 , 6 , 7 and 8 , and
b. a pharmaceutical excipient.